• / Free eNewsletters & Magazine
  • / My Account
Home>Funds>Pioneer Floating Rate

Pioneer Floating Rate

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. International Clinical Steering Committee Announced for Resverlogix's Phase 3 BETonMACE Clinical Trial with RVX-208 "apabetalone"

    International Clinical Steering Committee Announced for Resverlogix's Phase 3 BETonMACE Clinical Trial with RVX-208 "apabetalone"

  2. Florida Institute Funds Tampa-Based peerfit

    Florida Institute Funds Tampa-Based peerfit

  3. UPDATE: Fast and furious: What happened in the U.S. Treasury market?

    UPDATE: Fast and furious: What happened in the U.S. Treasury market?

  4. Novocure Selected as Technology Pioneer by World Economic Forum

    Novocure Selected as Technology Pioneer by World Economic Forum

  5. Soligenix Receives Orphan Drug Designation from the European Commission for SGX301 as a Treatment for Cutaneous T-Cell Lymphoma

    Soligenix Receives Orphan Drug Designation from the European Commission for SGX301 as a Treatment for Cutaneous T-Cell Lymphoma

  6. Soligenix Enters into a $10 Million Equity Purchase Agreement

    Soligenix Enters into a $10 Million Equity Purchase Agreement

  7. Capella University Unveils New Master of Social Work Degree Program

    Capella University Unveils New Master of Social Work Degree Program

  8. ONCODESIGN Announces the Creation of Its Scientific Advisory Board

    ONCODESIGN Announces the Creation of Its Scientific Advisory Board

  9. TRACT Therapeutics, Inc. Completes Phase I Safety Trial Using a Patient’s Immune Cells to Prevent Organ Rejection

    TRACT Therapeutics, Inc. Completes Phase I Safety Trial Using a Patient’s Immune Cells to Prevent Organ Rejection

  10. Research and Markets: Energy Harvesting: Off-Grid Renewable Power for Devices, Vehicles, Structures 2015-2025

    Research and Markets: Energy Harvesting: Off-Grid Renewable Power for Devices, Vehicles, Structures 2015-2025

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.